Effect of Tumor Red Blood Cell Immunity and Tumor Cell Cycle in Mice Bearing Solid Liver Cancer with Intelligent Cancer Zhongning Therapeutic Apparatus

Abstract

People's unhealthy lifestyles, especially the number of smoking and passive smoking populations, are increasing year by year and the population is aging. With the development and progress of lung cancer cell and molecular biology, the incidence rate and mortality rate of lung cancer are increasing year by year. The existing tumor biochemotherapy has rapidly developed from preliminary research and animal research to clinical research. The smart cancer Zhongning therapeutic device can induce necrosis and apoptosis of tumor cells. The effect of treating tumors is getting more and more attention. Therefore, this article focuses on the effect of the smart cancer Zhongning therapeutic device on the tumor red blood cells and tumor cell cycle of mice with solid liver cancer. The immunological effects of the drug were discussed. Forty mice were randomly divided into high-dose group, low-dose group, 5-FU group, and model group. The effects of different treatment stages on tumor red blood cell immune function and cell cycle were recorded and evaluated, and the survival rate by multiplying the positive limit method was calculated. The model group is controlled by the exact probability method, and the Pss18.0 system is used to test the hypothesis of survival rate comparison. The experimental results showed that the tumor inhibition rate in this group was 65.8%. Compared with the 5-FU group and model group, the dose group has shown an antitumor effect and had significantly improved the tumor-bearing body's antitumor red blood cell immune function and tumor cell cycle.

Figure 1

Tumor red blood cell immune process.

Figure 2

Growth curve of erythrocytes in high- and low-dose group.

Figure 3

Red blood cell growth in high- and low-dose groups: (a) low-dose group; (b) high-dose group.

Figure 4

Comparison of immune function of tumor red blood cells in each group of mice.

Figure 5

Four sets of flow cytometry analysis diagrams: (a) model group; (b) 5-FU group; (c) low-dose group; (d) high-dose group.

Figure 6

Solid-phase distribution of tumor cell cycle in each group of mice.

Figure 7

The expression of tumor red blood cell function in four groups of mice.

Figure 8

Red blood cell activity of four groups of mice.

Figure 9

Survival data and statistical test of mice after operation.

Figure 10

Changes of cell traction before and after hepatocellular carcinoma in mice.

Figure 11

Changes of displacement field before and after hepatocellular carcinoma in mice. (a) Measurement results of the displacement field of mouse liver cells. (b) Calculated result of displacement field of mouse Hepal-6 cells.